CBD is still a newcomer to formal medical research, but it is quickly garnering attention from scientists. One study reported that it effectively decreased chemically induced seizures in rats and mice.
Researchers have also observed how autism spectrum disorder symptoms such as anxiety and low anandamide levels can benefit from ASEA therapy.
It’s A Natural Pain Reliever.
CBDV has been getting the attention of most researchers. But what is CBDV? Cannabidivarin (CBDV), also known as cannabidiriviral venom (CVV), has generated international research interest due to its potential medicinal uses. Though less well-known than CBD or THC, CBDV still boasts similar antiemetic benefits that make it worth further investigation by scientists worldwide.
Studies show that CBDV can alleviate nausea. It impacts our brain’s glutamate system and increases the neurotransmitter GABA. CBDV may also serve as an anticonvulsant. This theory is supported by CBDV’s inability to bind with CB1 receptors like other cannabinoids do but rather interacting with TRPV1 (also known as vanilloid receptors).
Research into CBDV has revealed some promising results for treating the core symptoms of autism spectrum disorder (ASD). It improves social interaction and communication, reduces repetitive behaviors, and frees anxiety.
It’s An Anti-Inflammatory.
While CBDV research is still very new, it’s already gaining traction among pharmaceutical companies. This is mostly because it doesn’t exhibit the psychoactivity that makes most cannabis-derived medicines so controversial to medical professionals. CBDV is a member of the varinolic cannabinoids group (which features three carbons on their alkyl side chain). This subgroup has been shown to improve morphine analgesia through inhibition of glial activation and by suppressing the production of proinflammatory cytokines and chemokines in the brain. CBDV also reduces acute anxiety in neurodiverse people by shifting the balance between the stimulating neurotransmitter glutamate and the relaxing neurotransmitter anandamide.
It’s An Antiepileptic
CBDV, one of the lesser-known cannabinoids, may not garner as much media coverage as more widely-recognized cannabinoids like THC and CBD; however, it has recently garnered increasing attention in medical circles for its possible applications in treating seizures, mood regulation, antinausea properties, neuroprotection properties as well as mood regulating qualities. CBDV may even possess anti-nausea capabilities which have proven promising.
It’s A Stimulant.
Cannabidivarin, or CBDV, is a nonpsychoactive cannabinoid found in cannabis plants that has similar chemical structure as CBD but differing propyl chains instead of pentyl ones. Studies show CBDV to work as an anticonvulsant and help ameliorate symptoms associated with childhood intractable epilepsy; specifically it interacts with our TRPV1 receptors and desensitizes them, decreasing seizure severity.
Additionally, TRPV2 ion channels play a significant role in decreasing nervous system excitability, offering relief for pain, stress and anxiety while supporting muscle recovery and relaxation.
Although CBDV was first identified over 50 years ago, research on it only recently began to gain momentum. Its promising properties have made scientists and pharmaceutical companies take it more seriously.
It’s A Sleep Aid.
CBDV is relatively new to formal medical research, yet rapidly gaining momentum within pharmaceutical companies. Research on animal models indicates CBDV may stop chemically induced seizures as well as possibly treating Duchenne muscular dystrophy.
CBDV has recently demonstrated its potential to reduce acute anxiety levels among participants and increase anandamide levels in the brain. CBDV has also been investigated as potential support for individuals living with Rett syndrome (RTT), a neurological condition which typically affects girls and causes severe loss of coordination and speech. Anti-nausea properties seem promising. CBDV might stimulate CB1 receptors to block nausea responses.
